Novartis' BTK inhibitor meets primary endpoint in two MS trials, hints at improved safety
In two identical late-stage studies, Novartis' experimental BTK inhibitor Rhapsido markedly lowered the frequency of multiple sclerosis relapses. The oral therapy, already approved for chronic itch, could now gain a foothold in the MS treatment landscape. Preliminary results also point to a more favorable safety profile relative to existing options.
Rhapsido, an oral BTK inhibitor already on the market for chronic itch, met its primary endpoint in two identical late-stage multiple sclerosis trials by significantly reducing relapse frequency. The positive results suggest the therapy could expand into a new indication, leveraging its established approval pathway to accelerate regulatory review.
Preliminary safety data from the studies indicate a potentially more favorable profile compared to existing MS treatments, which often carry burdensome side effects. If confirmed, this could differentiate Rhapsido in a competitive landscape dominated by injectables and infusions, offering patients a convenient oral option with improved tolerability.
MS patients may gain a new oral therapy that could ease treatment burden and reduce side-effect-related discontinuation, potentially improving long-term adherence and quality of life. Healthcare systems could see cost shifts if this drug competes with established biologics, though pricing remains unknown. The safety signal, if validated, may pressure other developers to reassess their own BTK programs. However, long-term efficacy and real-world outcomes are still unproven, so clinical adoption would depend on confirmatory data and regulatory scrutiny.